{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:22:38Z","timestamp":1792592558670,"version":"4.5.0"},"reference-count":152,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cjca.2025.04.012","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T02:27:11Z","timestamp":1745029631000},"page":"1777-1793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Metabolic Dysfunction\u2013associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure"],"prefix":"10.1016","volume":"41","author":[{"given":"Bhavik","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fannie","family":"Lajeunesse-Trempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Keshvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2025.04.012_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cjca.2025.04.012_bib2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cjca.2025.04.012_bib3","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstrom","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cjca.2025.04.012_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.cjca.2025.04.012_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cjca.2025.04.012_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"suppl","key":"10.1016\/j.cjca.2025.04.012_bib7","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cjca.2025.04.012_bib8","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2025.04.012_bib9","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11897-013-0155-7","article-title":"The emerging epidemic of heart failure with preserved ejection fraction","volume":"10","author":"Oktay","year":"2013","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.cjca.2025.04.012_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","article-title":"Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes","volume":"126","author":"Steinberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.04.012_bib12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib13","doi-asserted-by":"crossref","unstructured":"Peikert A, Vaduganathan M, Claggett BL, et al. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial [e-pub ahead of print]. Eur Heart J https:\/\/doi.org\/10.1093\/eurheartj\/ehaf057.","DOI":"10.1093\/eurheartj\/ehaf057"},{"key":"10.1016\/j.cjca.2025.04.012_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cvr\/cvaa217","article-title":"Metabolic inflammation in heart failure with preserved ejection fraction","volume":"117","author":"Schiattarella","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2025.04.012_bib15","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2025.04.012_bib16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","article-title":"Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan","volume":"56","author":"Yoneda","year":"2021","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cjca.2025.04.012_bib18","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cjca.2025.04.012_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cjca.2025.04.012_bib20","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cjca.2025.04.012_bib21","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cjca.2025.04.012_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69013-y","article-title":"Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction","volume":"10","author":"Miller","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjca.2025.04.012_bib23","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ehf2.13250","article-title":"Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT","volume":"8","author":"Peters","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib24","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cjca.2025.04.012_bib25","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1161\/ATVBAHA.110.207340","article-title":"Serum gamma-glutamyl transferase and risk of heart failure in the community","volume":"30","author":"Dhingra","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2025.04.012_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.13012","article-title":"Fatty liver indices in the Multiethnic United States National Health and Nutrition Examination Survey","volume":"41","author":"Ruhl","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cjca.2025.04.012_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101333","article-title":"Non-alcoholic fatty liver disease, heart failure, and long-term mortality: insights from the National Health and Nutrition Examination Survey","volume":"47","author":"Minhas","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.cjca.2025.04.012_bib28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021654","article-title":"Nonalcoholic fatty liver disease and risk of heart failure among Medicare beneficiaries","volume":"10","author":"Fudim","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.04.012_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13098-023-01102-0","article-title":"Metabolic dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study","volume":"15","author":"Wei","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.cjca.2025.04.012_bib30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.3567","article-title":"Metabolic dysfunction-associated steatotic liver disease is associated with increased risks of heart failure","volume":"27","author":"Chang","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib31","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cjca.2025.04.012_bib32","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jchf.2023.10.016","article-title":"Association of hepatic triglyceride content with cardiac structure and function among community-dwelling adults","volume":"12","author":"Saha","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib33","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/liv.15556","article-title":"Fatty liver disease, heart rate and cardiac remodelling: evidence from the UK Biobank","volume":"43","author":"Jamialahmadi","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.cjca.2025.04.012_bib34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/hep.27869","article-title":"Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study","volume":"62","author":"VanWagner","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cjca.2025.04.012_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2024.05.010","article-title":"Association of disproportionate liver fat with markers of heart failure: the multi-ethnic study of atherosclerosis","volume":"275","author":"Kusner","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2025.04.012_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814292","article-title":"Non-alcoholic fatty liver disease and echocardiographic parameters of left ventricular diastolic function: a systematic review and meta-analysis","volume":"24","author":"Goliopoulou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2025.04.012_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014279","article-title":"Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study","volume":"9","author":"VanWagner","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.04.012_bib38","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2025.04.012_bib39","first-page":"352","volume":"23","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","article-title":"Impact of obesity on plasma natriuretic peptide levels","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.04.012_bib41","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.metabol.2016.02.001","article-title":"Computerized tomography measured liver fat is associated with low levels of N-terminal pro-brain natriuretic protein (NT-proBNP). Multi-Ethnic Study of Atherosclerosis","volume":"65","author":"Sanchez","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.cjca.2025.04.012_bib42","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1093\/eurheartj\/ehac121","article-title":"BNP: Biomarker not perfect in heart failure with preserved ejection fraction","volume":"43","author":"Shah","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.04.012_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jamacardio.2017.4208","article-title":"Natriuretic peptide deficiency---when there is too little of a good thing","volume":"3","author":"Wang","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2025.04.012_bib44","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","article-title":"Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality","volume":"43","author":"Verbrugge","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.04.012_bib45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol Rev Camb Philos Soc"},{"key":"10.1016\/j.cjca.2025.04.012_bib46","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cjca.2025.04.012_bib47","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11906-023-01242-8","article-title":"Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease","volume":"25","author":"Badmus","year":"2023","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.cjca.2025.04.012_bib49","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jhep.2024.10.044","article-title":"Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease","volume":"82","author":"Kim","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cjca.2025.04.012_bib50","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s12072-024-10660-y","article-title":"MAFLD as part of systemic metabolic dysregulation","volume":"18","author":"Zhao","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cjca.2025.04.012_bib51","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/joim.12728","article-title":"Manifestations and mechanisms of myocardial lipotoxicity in obesity","volume":"284","author":"Sletten","year":"2018","journal-title":"J Intern Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib52","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart--an engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib53","first-page":"860","article-title":"Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction","volume":"33","author":"De Jong","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2025.04.012_bib54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fcvm.2018.00068","article-title":"Loss of metabolic flexibility in the failing heart","volume":"5","author":"Karwi","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib55","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.108.792101","article-title":"Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart","volume":"119","author":"Boudina","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.04.012_bib56","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1161\/CIRCRESAHA.113.302095","article-title":"Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes","volume":"113","author":"Kolwicz","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2025.04.012_bib57","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1128\/MCB.01109-14","article-title":"Enhanced cardiac Akt\/protein kinase B signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-targeted nuclear genes","volume":"35","author":"Wende","year":"2015","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.cjca.2025.04.012_bib58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/eurheartj\/ehp396","article-title":"Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction","volume":"31","author":"Cook","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.04.012_bib59","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1172\/JCI40096","article-title":"Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents","volume":"120","author":"Shimizu","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cjca.2025.04.012_bib60","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jama.294.3.334","article-title":"Insulin resistance and risk of congestive heart failure","volume":"294","author":"Ingelsson","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2025.04.012_bib61","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1152\/physrev.00033.2011","article-title":"Pathophysiology of human visceral obesity: an update","volume":"93","author":"Tchernof","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.cjca.2025.04.012_bib62","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.cmet.2014.10.010","article-title":"Loss of white adipose hyperplastic potential is associated with enhanced susceptibility to insulin resistance","volume":"20","author":"Kim","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.cjca.2025.04.012_bib63","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2021.04.003","article-title":"Pericardial fat and the risk of heart failure","volume":"77","author":"Kenchaiah","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.04.012_bib64","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1186\/s12916-022-02672-y","article-title":"Obese visceral fat tissue inflammation: from protective to detrimental?","volume":"20","author":"Kolb","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102870","article-title":"TNFalpha is a key trigger of inflammation in diet-induced non-obese MASLD in mice","volume":"66","author":"Burger","year":"2023","journal-title":"Redox Biol"},{"key":"10.1016\/j.cjca.2025.04.012_bib66","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db11-0828","article-title":"Stress augments insulin resistance and prothrombotic state: role of visceral adipose-derived monocyte chemoattractant protein-1","volume":"61","author":"Uchida","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.cjca.2025.04.012_bib67","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/CIRCRESAHA.124.324829","article-title":"Systems biology approach uncovers candidates for liver-heart interorgan crosstalk in HFpEF","volume":"135","author":"Strocchi","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2025.04.012_bib68","first-page":"1489","article-title":"Relationships between periventricular epicardial adipose tissue accumulation, coronary microcirculation, and left ventricular diastolic dysfunction","volume":"33","author":"Nakanishi","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2025.04.012_bib69","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ejechocard\/jep002","article-title":"Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives","volume":"10","author":"Natale","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.cjca.2025.04.012_bib70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2010.05.034","article-title":"Perivascular adipose tissue as a cause of atherosclerosis","volume":"214","author":"Verhagen","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2025.04.012_bib71","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1148\/radiol.14132952","article-title":"Nonalcoholic fatty liver disease: portal hypertension due to outflow block in patients without cirrhosis","volume":"274","author":"Hirooka","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.cjca.2025.04.012_bib72","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/liv.12791","article-title":"Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment","volume":"35","author":"Raevens","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.cjca.2025.04.012_bib73","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007308","article-title":"Extracardiac abnormalities of preload reserve: mechanisms underlying exercise limitation in heart failure with preserved ejection fraction, autonomic dysfunction, and liver disease","volume":"14","author":"Fudim","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib74","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.23736\/S0022-4707.19.09231-4","article-title":"Aerobic capacity and exercise performance in nonalcoholic fatty liver disease","volume":"59","author":"Austin","year":"2019","journal-title":"J Sports Med Phys Fitness"},{"key":"10.1016\/j.cjca.2025.04.012_bib75","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41440-024-01708-5","article-title":"Temporal relationship between hepatic steatosis and blood pressure elevation and the mediation effect in the development of cardiovascular disease","volume":"47","author":"Hu","year":"2024","journal-title":"Hypertens Res"},{"key":"10.1016\/j.cjca.2025.04.012_bib76","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1097\/HJH.0b013e3283576faf","article-title":"High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults","volume":"30","author":"Vasunta","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjca.2025.04.012_bib77","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/HJH.0000000000000532","article-title":"Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk","volume":"33","author":"Aneni","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjca.2025.04.012_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.942753","article-title":"Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality","volume":"9","author":"Ng","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib79","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib80","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/eurheartj\/ehp490","article-title":"New insights into the relationship of left ventricular geometry and left ventricular mass with cardiac function: a population study of hypertensive subjects","volume":"31","author":"Chahal","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.04.012_bib81","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/apt.15738","article-title":"Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis","volume":"51","author":"Carlsson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cjca.2025.04.012_bib82","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1210\/clinem\/dgae264","article-title":"LDL-C and TC mediate the risk of PNPLA3 inhibition in cardiovascular diseases","volume":"110","author":"Zhang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cjca.2025.04.012_bib83","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1002\/ehf2.15019","article-title":"Non-alcoholic fatty liver disease and heart failure: a comprehensive bioinformatics and Mendelian randomization analysis","volume":"11","author":"Zhang","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib84","article-title":"Identification of common signature genes and pathways underlying the pathogenesis association between nonalcoholic fatty liver disease and heart failure","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.cjca.2025.04.012_bib85","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.124.010912","article-title":"Risk of major adverse cardiovascular outcomes in families with MASLD: a population-based multigenerational cohort study","volume":"17","author":"Ebrahimi","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjca.2025.04.012_bib86","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.29285","article-title":"FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients","volume":"66","author":"So-Armah","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cjca.2025.04.012_bib87","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.04.012_bib88","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.04.012_bib89","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jchf.2020.10.013","article-title":"Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes","volume":"9","author":"Pandey","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib90","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cjca.2025.04.012_bib91","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.116.025629","article-title":"Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment","volume":"135","author":"Sundstrom","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.04.012_bib92","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.119.044865","article-title":"Association of intensive lifestyle intervention, fitness, and body mass index with risk of heart failure in overweight or obese adults with type 2 diabetes mellitus: an analysis from the Look AHEAD Trial","volume":"141","author":"Pandey","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.04.012_bib93","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes: the LookAHEAD trial","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib94","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.120.050941","article-title":"Association of baseline and longitudinal changes in body composition measures with risk of heart failure and myocardial infarction in type 2 diabetes: findings from the Look AHEAD Trial","volume":"142","author":"Patel","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.04.012_bib95","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc10-0856","article-title":"Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes","volume":"33","author":"Lazo","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2025.04.012_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263931","article-title":"Lifestyle changes in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"17","author":"Fernandez","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2025.04.012_bib97","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.jacc.2019.01.067","article-title":"Dietary patterns and incident heart failure in U.S. adults without known coronary disease","volume":"73","author":"Lara","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.04.012_bib98","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jama.2017.0947","article-title":"Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States","volume":"317","author":"Micha","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2025.04.012_bib99","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1186\/s12889-024-19378-w","article-title":"Efficacy of the Mediterranean diet in treating metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents: a systematic review and meta-analysis","volume":"24","author":"Jamil","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.cjca.2025.04.012_bib100","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCHEARTFAILURE.113.000495","article-title":"Mediterranean and DASH diet scores and mortality in women with heart failure: the Women's Health Initiative","volume":"6","author":"Levitan","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib101","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ejhf.750","article-title":"Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial","volume":"19","author":"Papadaki","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2025.04.012_bib102","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00394-023-03221-w","article-title":"Dietary approaches to stop hypertension (DASH) diet improves hepatic fibrosis, steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomized controlled trial","volume":"63","author":"Sangouni","year":"2024","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.cjca.2025.04.012_bib103","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/CIRCULATIONAHA.117.030617","article-title":"Reversing the cardiac effects of sedentary aging in middle age---a randomized controlled trial: implications for heart failure prevention","volume":"137","author":"Howden","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.04.012_bib104","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacc.2016.11.081","article-title":"relationship between physical activity, body mass index, and risk of heart failure","volume":"69","author":"Pandey","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.04.012_bib105","first-page":"85","article-title":"Supervised exercise versus non-supervised exercise for reducing weight in obese adults","volume":"49","author":"Nicolai","year":"2009","journal-title":"J Sports Med Phys Fitness"},{"key":"10.1016\/j.cjca.2025.04.012_bib106","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1161\/CIR.0000000000001122","article-title":"Supervised exercise training for chronic heart failure with preserved ejection fraction: a scientific statement from the American Heart Association and American College of Cardiology","volume":"147","author":"Sachdev","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.04.012_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.cjca.2025.04.012_bib108","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib111","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity---a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib112","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.04.012_bib113","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib114","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib115","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib116","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib117","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib118","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","article-title":"The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction","volume":"117","author":"Withaar","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2025.04.012_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101641","article-title":"Glucagon-like peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction","volume":"66","author":"McLean","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.cjca.2025.04.012_bib120","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","article-title":"A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity","volume":"127","author":"Noyan-Ashraf","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.04.012_bib121","first-page":"1816","article-title":"Biology and clinical use of glucagon-like peptide-1 receptor agonists in vascular protection","volume":"39","author":"Yau","year":"2023","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2025.04.012_bib122","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.cjca.2025.04.012_bib123","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.cjca.2025.04.012_bib124","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"issue":"suppl 4","key":"10.1016\/j.cjca.2025.04.012_bib125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cjca.2025.04.012_bib126","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.cmet.2024.08.005","article-title":"SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8(+) T cell activation","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.cjca.2025.04.012_bib127","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eprac.2024.11.017","volume":"31","author":"Xu","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.cjca.2025.04.012_bib128","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.04.012_bib129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.04.012_bib130","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2025.04.012_bib131","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cjca.2025.04.012_bib132","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib133","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cjca.2025.04.012_bib134","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cjca.2025.04.012_bib135","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib136","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S2468-1253(23)00198-X","article-title":"Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"8","author":"Noureddin","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cjca.2025.04.012_bib137","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jamacardio.2025.0103","article-title":"Novel controlled metabolic accelerator for obesity-related HFpEF: the HuMAIN-HFpEF randomized clinical trial","volume":"10","author":"Pandey","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2025.04.012_bib138","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3390\/ijms26041778","article-title":"Current therapeutic landscape for metabolic dysfunction-associated steatohepatitis","volume":"26","author":"Devasia","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2025.04.012_bib139","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.cjca.2025.04.012_bib140","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib141","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib142","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.04.012_bib143","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cjca.2025.04.012_bib144","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2025.04.012_bib145","doi-asserted-by":"crossref","first-page":"12626","DOI":"10.1021\/acs.jmedchem.2c00660","article-title":"Discovery and optimization of the first highly effective and orally available galectin-3 inhibitors for treatment of fibrotic disease","volume":"65","author":"Zetterberg","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.cjca.2025.04.012_bib146","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1007\/s00392-023-02250-z","article-title":"Non-alcoholic fatty liver disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients","volume":"112","author":"Roderburg","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cjca.2025.04.012_bib147","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-021-01374-8","article-title":"The association of hepatic steatosis and fibrosis with heart failure and mortality","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cjca.2025.04.012_bib148","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/diagnostics12030663","article-title":"Non-alcoholic fatty liver disease defined by fatty liver index and incidence of heart failure in the Korean population: a nationwide cohort study","volume":"12","author":"Han","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.cjca.2025.04.012_bib149","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12933-024-02489-4","article-title":"Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure","volume":"23","author":"Oh","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cjca.2025.04.012_bib150","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jcmg.2016.10.024","article-title":"Pericardial, but not hepatic, fat by CT is associated with CV outcomes and structure: the multi-ethnic study of atherosclerosis","volume":"10","author":"Shah","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2025.04.012_bib151","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/liv.14600","article-title":"The association of non-alcoholic fatty liver disease and cardiac structure and function---Framingham Heart Study","volume":"40","author":"Chiu","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.cjca.2025.04.012_bib152","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead108","article-title":"Association between non-alcoholic fatty liver disease and subclinical left ventricular dysfunction in the general population","volume":"3","author":"Hirose","year":"2023","journal-title":"Eur Heart J Open"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25003150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25003150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T23:59:16Z","timestamp":1765324756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X25003150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":152,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0828282X25003150"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2025.04.012","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Metabolic Dysfunction\u2013associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2025.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}